March 23 (Bloomberg) -- Shares of Genentech Inc., the world’s second-biggest biotechnology company, fell the most in two years after first-quarter sales stalled and researchers halted a study of the cancer drug Avastin.
March 23 (Bloomberg) -- Shares of Genentech Inc., the world’s second-biggest biotechnology company, fell the most in two years after first-quarter sales stalled and researchers halted a study of the cancer drug Avastin.
